PharmaCyte Biotech, Inc.
PharmaCyte Biotech, Inc. (PMCB) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · PMCB · as of Jun 8, 2026
Key Statistics
Explore PharmaCyte Biotech, Inc. Data
pmcb stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 1 · Buy rate: 0.0%
Competitors & Peers
pmcb competitorsPMCB
BCLI
CYCN
IBO
KTTA
NBYStock Performance
Full HistoryAbout PharmaCyte Biotech, Inc.
PharmaCyte Biotech, Inc. is a biotechnology firm dedicated to the development and commercialization of advanced cellular therapies within the United States. Their primary therapeutic areas include var…
what is pharmacyte biotech, inc. · pmcb stock overview · pharmacyte biotech, inc. company profile · who is pharmacyte biotech, inc. ceo · pmcb NASDAQ · pharmacyte biotech, inc. headquarters · pharmacyte biotech, inc. business segments
About Stock Overview & Key Data
PharmaCyte Biotech, Inc. (PMCB) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jan 2, 2013. As of the latest trading session, PMCB stock price is $0.70, with a market capitalization of $4.8M. The stock has returned -32.69% over the past 12 months and -3.31% year-to-date.
According to 1 Wall Street analysts, the consensus rating for PharmaCyte Biotech, Inc. stock is Hold, with an average 12-month price target of $—. In fiscal year 2025, PharmaCyte Biotech, Inc. reported revenue of — and net income of $30.7M. For detailed data — including PharmaCyte Biotech, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, PharmaCyte Biotech, Inc. (PMCB) stock price is $0.70. The stock is traded on NASDAQ under the ticker symbol PMCB. The 52-week range is $0.63 – $1.51.